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Purpose: Open revascularization in patients with chronic mesenteric ischemia (CMI) is considered the gold standard.
Percutaneous transluminal angioplasty and stenting (PTAS) is often reserved for patients not suitable for open
revascularization. In our institute, endovascular revascularization is the first-choice treatment. The purpose of this study
was to report the technical and clinical success rates after endovascular revascularization as the first-choice treatment in
a series of 51 consecutive patients with CMI at a single tertiary vascular referral center.
Methods: A retrospective review was performed of all consecutive patients with CMI who underwent PTAS from July 2001 to
July 2008. Only symptomatic patients treated for atherosclerotic CMI were included. Patency was evaluated using computed
tomography angiography (CTA). Kaplan-Meier curves were used to calculate patency rates of the treated mesenteric arteries.
Results: Sixty mesenteric arteries (30 celiac trunks, 24 superior mesenteric, and 6 inferior mesenteric arteries) were treated
in 51 patients (26 men). Major morbidity was 4%. After dissection of the superior mesenteric artery (n  1) and brachial
artery (n  1), respectively, both patients underwent endarterectomy and patch plasty. In three arteries, the lesion could
not be crossed endovascularly and they were deemed immediate intention-to-treat failures. The initial technical success
rate was 93%. No 30-day mortality was observed. Median follow-up was 25 months. During follow-up, 2 patients died
from intestinal ischemia. Complete symptom relief was achieved in 78% of patients. Primary 1- and 2-year patency rates
were 86%  5% and 60%  9%, respectively; primary-assisted patency rates were 88%  5% and 79%  7%, respectively.
During follow-up, 6 patients underwent open revascularization due to failure of PTAS.
Conclusion: The initial technical success rate of PTAS as first-choice treatment of CMI is >90%. The 2-year primary
patency rate dropped to 60%, but symptomatic in-stent stenoses could often be treated successfully with renewed
endovascular techniques. Including one conversion, 14% of patients needed open revascularization during follow-up.
(J Vasc Surg 2010;51:386-91.)Chronic mesenteric ischemia (CMI) is an uncommon
disease. The symptoms may be nonspecific and vary from the
classical triad of postprandial abdominal pain, weight loss, and
upper abdominal bruit to nonspecific abdominal pain and
intermittent diarrhea. Open surgical treatment with bypass or
endarterectomy has been the standard for many years.1-4
Although the long-termoutcome after open revascularization
is both anatomically and functionally adequate, it is associated
with substantial morbidity and mortality.4,5
An alternative treatment for patients with CMI is percu-
taneous transluminal angioplasty and stenting (PTAS). Sev-
eral reports have compared endovascular with open surgical
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386revascularization in patients with CMI.2,3,6-8 They document
decreased morbidity and mortality rates and acceptable func-
tional outcome after PTAS, but this therapy was reserved for
patients not suitable for open revascularization.
The goal of this study was to report the technical and
clinical success rates after endovascular revascularization as
the first-choice treatment in a series of 51 consecutive and
unselected patients with CMI at a single tertiary vascular
referral center.
METHODS
A retrospective review was performed on all consecu-
tive patients with CMI from July 2001 to July 2008. All
patients were treated with PTAS. Patients were identified
from a vascular intervention database. Patients presenting
with long-standing symptoms suggestive of CMI (post-
prandial abdominal pain, weight loss, and abdominal bruit)
and visceral obstructive disease on vascular imaging were
discussed in the multidisciplinary workgroup consisting of
interventional radiologists, gastroenterologists, and vascu-
lar surgeons. Visceral obstructive disease was identified with
Doppler ultrasound (DUS) scan imaging, magnetic reso-
nance angiography (MRA), or computed tomography an-
giography (CTA). DUS criteria for stenosis were adapted
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noses were excluded by abdominal CT and gastroscopy or
colonoscopy, or both, on indication. Since 2007, we have
also performed gastric and jejunal exercise tonometry on
indication.10,11 In patients with high suspicion for CMI,
the diagnosis was obtained by digital subtraction angiogra-
phy (DSA) with the option of immediate treatment. Only
symptomatic patients treated for atherosclerotic CMI (sig-
nificant stenosis or occlusion of at least two of three mes-
enteric arteries or single-vessel disease without collateral
circulation) were included. Patients with acute mesenteric
ischemia, acute exacerbation of CMI, thromboembolic vis-
ceral disease, or aortic dissection were excluded. All patients
underwent first-time procedures. Hospital records were
reviewed for demographics, symptoms, lesion characteris-
tics, details of treatment, and outcome.
Arterial access was obtained by a transfemoral (80%) or
transbrachial approach (8%), or both (12%). All patients
underwent systemic heparinization with 5000 IE. After
placement of a 6F catheter sheath and introduction of a
diagnostic catheter, an anteroposterior and lateral abdom-
inal aortography was taken. The mesenteric arteries were
cannulated with a reversed curved or angled catheter, and
the outflow bed was evaluated for collateral circulation. A
stenosis of70% on DSA or a mean pressure gradient of at
least 10 mm Hg across the lesion was considered hemody-
namically significant.12,13 Pressure gradients were only
measured in doubtful hemodynamically significant lesions
prior to treatment or in persistent stenosis after treatment.
Sufficient collateral circulation was defined as rapid filling of
the diseased visceral artery by the gastroduodenal or pan-
creaticoduodenal arteries, the marginal artery of Drum-
mond or the arc of Riolan. In case of small collaterals
without rapid filling of the diseased visceral artery, collateral
circulation was considered insufficient. At this point, the
diagnosis of CMI was assessed or rejected. The treatment
was focused on the superior mesenteric artery (SMA). In
patients with long SMA occlusions and a significant celiac
artery (CA) or inferior mesenteric artery (IMA) stenosis,
one of the latter vessels were treated, and collateral circula-
tion to the SMAwas assessed. After the stenosis was crossed
or recanalization of the occlusion was achieved with a
0.035-inch wire, PTAS was performed. All stents were
slightly oversized by approximately 10% based on proposed
normal diameter. The stenosis was predilated if necessary.
No embolic protection devices were used.
Technical success was defined as a residual diameter
reduction 30% after PTAS of the obstruction or a pres-
sure gradient 5 mm Hg across the lesion.14 A technical
failure was defined as an occlusion or stenosis that could not
be crossed or dilated, or a residual stenosis of 30%. In
patients with single-vessel disease without sufficient collat-
eral circulation, this artery was treated. In case of insuffi-
cient collateral circulation from the treated artery or an
intention-to-treat failure, a second artery was treated by
PTAS. A complication was defined as any unintentional
event resulting from the treatment that led to adjustment of
medical treatment or irreversible damage.Clinical success was defined as technical success in at
least one artery with sufficient collateral circulation and the
resolution of symptoms and weight gain at least 3 months
after the procedure, or both.14 PTAS was considered the
first-choice treatment in all patients. If the endovascular
treatment failed, a visceral bypass was considered. All pa-
tients were prescribed aspirin (100 mg daily) after the
procedure. In addition, clopidogrel was prescribed for 1
month after stent placement in all patients.15
Regular follow-up consisted of anamnesis and physical
examination after 3 months and yearly thereafter. If the pa-
tient had complete symptom relief, no additional imagingwas
performed. In December 2008, all patients were interviewed
and invited for a physical examination and CTA.
Statistical analysis. Measured values are reported as
mean 1 SD or median (range), as appropriate. Technical
success and patency rates were based on a per-artery analy-
sis. Clinical success was based on a per-patient analysis.
Kaplan-Meier curves were used to estimate patency and
success rates. They were presented as percent  SEM.14,16
Pearson’s 2 test was used to determine differences be-
tween groups. Significance was established at P  .05.
Analysis was performed using SPSS 15.0 software (SPSS
Inc, Chicago, Ill).
RESULTS
Technical success. A total of 69 patients with sus-
pected CMI underwent DSA. PTAS was not performed in
18 patients. In 6 patients, compression of the celiac artery
by the arcuate ligament was observed. In the other patients,
either a significant stenosis was not assessed, or abundant
collateral circulation to the diseased artery was observed.
Sixty mesenteric arteries (30 celiac, 24 superior mesenteric,
and 6 inferior mesenteric arteries) were treated in 51 pa-
tients (26 men). Mean age was 64  11 years. In 14 of the
51 patients, complete occlusion of the SMA was observed.
In 11 of 14 patients, a stenosis in the celiac trunk was
successfully treated by PTAS, and the SMA was left un-
treated. In 2 patients, the IMA was treated successfully. In
the remaining patient, both the celiac trunk and SMA were
occluded, and recanalization of both arteries was only
successful for the SMA. All other treated vessels contained
a hemodynamically significant stenosis (70%). All patients
underwent PTAS using short balloon-expandable stents
with a median length of 14 mm (8-24 mm). Median stent
diameter placed in the celiac trunk was 6 mm (5-7 mm); in
the SMA, 6 mm (4.5-7 mm); and in the IMA, 5 mm (4-6
mm). In 3 patients, the obstruction (1 occlusion, 2 steno-
ses) in the celiac trunk could not be crossed endovascularly,
and they were deemed immediate intention-to-treat fail-
ures. In all of the patients with an initial failure, a second
mesenteric artery was successfully treated by PTAS during
the same procedure. A fourth intention-to-treat failure was
registered after dissection of the SMA occurred that could
not be restored endovascularly. This patient underwent
endarterectomy and patch plasty of the dissected artery.
The initial technical success rate was 93% (56 of 60
arteries).
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the only initial conversion, another major complication was
observed in a second patient. Dissection at the access site
developed, and this patient underwent endarterectomy and
patch plasty of the brachial artery. In 3 other patients, a
hematoma was observed at the transfemoral access site
without need for surgical intervention. This resulted in a
major complication rate of 4% (2 of 51 procedures). The
30-day mortality rate was 0%.
Median follow-up was 25 months. In 39 of 51 patients
(76%), anatomic follow-up was obtained. Primary 1-year
and 2-year patency rates were 86%  5% and 60%  9%,
respectively, and assisted primary patency rates were 88%
5% and 79%  7% (Fig 1).
Clinical success. Patients presented predominantly
with postprandial pain and weight loss (Table I). Successful
PTAS of a second mesenteric artery in patients with an
intention-to-treat failure eventually resulted in clinical suc-
cess in these patients. Technical failure of PTAS resulted in
clinical failure in 1 patient who required conversion after
dissection of the SMA. Ten other patients did not have
complete symptom relief after 3 months, resulting in an
initial clinical success rate of 78%  6% (Fig 2). In 6
patients, two visceral arteries were treated successfully, re-
sulting in initial clinical success (after 3 months) in all
patients. After successful treatment of only one visceral
artery, initial clinical success was observed in 34 of 45
patients (P  .171).
Twenty patients suffered from two-vessel disease and
24 from three-vessel disease. Seven patients suffered from
single-vessel disease in the absence of collateral circulation
to the diseased artery on DSA (Table II). In 5 of 7 patients,
the celiac trunk was treated, and the SMA was treated in 2
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Fig 1. Kaplan-Meier primary (interrupted line) and assisted pri-
mary patency (continuous line) rates of 60 mesenteric arteries
treated by percutaneous transluminal angioplasty.patients. Four of 7 patients presented with typical postpran-dial pain in combination with weight loss. After PTAS, 3 of
7 patients were asymptomatic, and 1 had only partial im-
provement. In 3 patients, persistent complaints were ob-
served. In 2 patients, symptom relief was obtained by
treatment of Helicobacter pylori (n  1) and Clostridium
difficile infection (n  1), respectively. In the remaining
patient, PTAS treatment of the CA was technically success-
ful, but her nausea and vomiting complaints did not im-
prove. The patient died of pneumonia 4 months later. After
PTAS in patients suffering from two-vessel disease, 5 of 20
patients did not have complete symptom relief. Three pa-
tients had only partial improvement. One patient under-
went an SMA bypass, and another patient underwent an
endarterectomy of SMA due to dissection. After PTAS in
patients suffering from three-vessel disease, 2 patients did
not have complete symptom relief. One patient had partial
improvement, and the other patient underwent an SMA
bypass (Fig 2). The difference in symptom relief after PTAS
in patients with single- and multi-vessel disease was statis-
tical significant (P  .014).
During a median follow-up of 25 months, symptoms
relapsed in 13 of the 40 patients with initial complete
symptom relief. Relapse of symptoms was observed only in
patients with multi-vessel disease. In 12 of 13 patients with
symptom relapse, CTA showed restenosis of the treated
mesenteric artery. Five patients underwent successful per-
cutaneous transluminal angioplasty (PTA) of an in-stent
stenosis. The other 8 patients had mild symptoms and were
monitored without renewed intervention. In another 6
patients, significant restenosis was identified in the treated
mesenteric artery without symptom relapse. Two patients
died during follow-up of intestinal ischemia. Both patients
had withdrawn from follow-up and presented with acute
mesenteric ischemia. Twelve patients died of causes not
related to the CMI, of which 6 were cardiovascular deaths.
During follow-up, recurrence of symptoms after treatment
of two visceral arteries was similar to treatment of one
Table I. Comorbidity and presenting symptoms in 51
patients with chronic mesenteric ischemia
Factor Number Percentage
Male 26 51
Smoking 29 57
Hypertension 37 73
Hypercholesterolemia 32 63
Diabetes 6 12
Renal disease 17 33
CAD 23 45
COPD 9 18
Previous vascular surgery 20 39
Postprandial abdominal pain 47 92
Weight lossa 32 63
Diarrhea 12 24
Intestinal ulcer 6 12
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease.
aWeight loss was defined as at least 5 kg in a period 6 months.visceral artery (P  .962). The primary 1-year and 2-year
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respectively, and assisted primary clinical success rates were
72%  6% and 68%  7% (Fig 3).
PTAS failed during follow-up in 6 patients, and they
underwent open revascularization. The first 2 patients un-
derwent successful PTAS of a stenosed celiac trunk, and the
occluded SMA was left untreated. When symptoms did not
resolve after 1 month, a common iliac artery SMA bypass
was performed, as mentioned above. The third patient
underwent PTAS of a stenosed celiac trunk. The occluded
SMA and stenosed IMA were left untreated. A DSA
showed scant collateral circulation. Although symptoms
resolved, a common iliac artery SMA bypass was per-
formed. The fourth patient underwent PTAS of the celiac
trunk, but the occluded SMA was left untreated. After 2
years, successful PTA of an in-stent stenosis in the celiac
trunk was performed. Postprandial pain and weight loss
returned 9 months later, and open revascularization was
performed using an antegrade bifurcated bypass to the
hepatic artery and SMA. The fifth patient underwent suc-
cessful PTAS of a stenosed SMA, but endovascular treat-
ment of the stenosis in the celiac trunk failed. The occluded
IMA was left untreated. Restenosis of the SMA occurred
after 25 months and was treated by PTA. Although tech-
nically successful, postprandial pain and weight loss did not
resolve, and open revascularization was performed using an
antegrade bifurcated bypass to the hepatic artery and SMA.
Fig 2. Clinical success in 51 patients treated for chron
angioplasty and stenting (PTAS).
Table II. Initial clinical success after PTAS in patients
suffering from single-vessel and multivessel disease
Number of diseased visceral
arteries Patients
Complete symptom
relief
1 7 3
2 20 15
3 24 22
Total 51 40
PTAS, Percutaneous transluminal angioplasty and stenting.The sixth patient underwent recanalization and stent place-ment of a totally occluded SMA, but recanalization of the
totally occluded celiac trunk failed. Four years after PTAS,
the patient presented with acutemesenteric ischemia due to
occlusion of the recanalized SMA. Open revascularization
consisting of a retrograde SMA bypass was performed;
unfortunately, the patient died the first day after surgery.
All bypasses were anastomosed distally from the stent, and
this was not associated with technical difficulties.
DISCUSSION
Endovascular treatment as first-choice treatment for
patients with CMI appears to be a safe therapy with initial
technical and clinical success rates similar to open revascu-
larization.1,2,17 During midterm follow-up, substantial re-
currence of symptoms has been observed. In the current
senteric ischemia (CMI) by percutaneous transluminal
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Fig 3. Kaplan-Meier primary (interrupted line) and assisted pri-
mary clinical success (continuous line) rates in 51 patients with
chronic mesenteric ischemia treated by percutaneous transluminal
angioplasty.ic meseries, we have treated unselected patients endovascularly,
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of this series might be better for comparison with the
findings after open revascularization, since PTAS has often
been reserved for patients unfit for open revascularization.
Open revascularization is associated with substantial
morbidity and mortality. Reported morbidity ranges from
12% to 33%.17,18 Two major complications (4%) were
observed in our series, and no patients died as a result of
PTAS. In a series from a nationwide database in the United
States, more than 5500 patients were treated for CMI. The
mortality rate of 3.7% after PTAS was significantly lower
than the 13% after bypass.4 In the largest recent series from
specialized centers, the mortality rate after open revascular-
ization ranges from 2% to 15%.1-3,6,7
The initial technical success rate in our series was 93%.
Seven patients (14%) eventually underwent open revascu-
larization after PTAS failure. In only 1 patient did PTAS
have to be converted immediately to endarterectomy due
to dissection of the treated artery. Three other patients
underwent open revascularization within 3 months after
PTAS. During follow-up, 3 more patients underwent open
revascularization after late failure of PTAS.
Although endarterectomy and antegrade and retro-
grade bypasses are associated with significant rates of mor-
bidity and mortality, open revascularization provides dura-
ble symptom relief. After open revascularization, excellent
long-term clinical success rates up to 92% after 5 years have
been reported.1,2,6,7 It has been considered the standard
for many years. In a review of 292 patients treated by PTAS,
symptom relief without reintervention was maintained in
75% of these patients.15 In our current series, symptoms
with varying severity had recurred in 13 of 40 patients after
a median follow-up of 25 months. The 2-year primary
clinical success rate had dropped to 56%. However, the
symptomatic restenoses in most patients could again be
treated endovascularly, resulting in a 2-year primary-
assisted clinical success rate of 68%. It appears that the
results after endovascular revascularization are not as dura-
ble as after open revascularization.
A critical point in treating patients with CMI—both
open and endovascularly—is adequate diagnostic studies.
Imaging studies to identify the presence of mesenteric
artery obstructive disease include DUS, MRA, CTA, and
DSA. CMI is suspected in patients with at least two mes-
enteric arteries demonstrating a hemodynamically signifi-
cant stenosis or occlusion. Single-vessel disease without
collaterals may also lead to symptomatic CMI. Treatment
of asymptomatic patients with a significant celiac trunk or
SMA stenosis has not been recommended. The presence of
an asymptomaticmesenteric artery stenosis is not associated
with death or adverse cardiologic events, and these patients
do not develop chronic intestinal ischemia or intestinal
infarction.19 Only asymptomatic patients with significant
three-vessel arterial disease should be considered for pro-
phylactic mesenteric arterial revascularization.20 Symptoms
can be nonspecific, and typical symptoms are not always the
result of mesenteric ischemia.Failure of symptom relief after successful PTAS or open
revascularization might result from an incorrect diagnosis.
In our series, at least 3 patients with an incorrect diagnosis
underwent PTAS. Two patients did not obtain symptom
relief before eradication therapy for Helicobacter pylori and
Clostridium difficile. In the third patient, a proper explana-
tion for the nausea, vomiting, and chronic diarrhea not
responding to PTAS was never found.
Gastric exercise tonometry is a functional test that can
be used as an addition to anatomic imaging.10 In our series,
the clinical outcome after treatment of patients with single-
vessel disease was disappointing and significantly worse
compared to patients with multi-vessel disease. Especially
in these patients, a functional test could have additional
value to identify gastrointestinal ischemia. In a series of 95
patients treated for CMI, 84% had durable and complete
symptom relief after surgical revascularization or endovas-
cular stent placement. Prior to the revascularization, 85% of
patients had abnormal results on gastric exercise tonome-
try. Of the patients with a single-vessel stenosis, 38 of 50
were free from symptoms, compared with 32 of 35 with
multiple-vessel stenoses (P  .086).2 This test was used in
only 3 of our patients but seems to have additional value in
selected patients.
In this retrospective series, morbidity and mortality
rates after endovascular revascularization as first-choice
treatment in patients with CMI are low compared with
reported outcomes after open revascularization. The initial
technical success rate of PTAS was 90%. The 2-year
primary patency and clinical success rate is only reasonable,
and in-stent stenoses can often be treated successfully with
repeated endovascular techniques. Although one initial
conversion was observed, only 14% of patients needed open
revascularization during midterm follow-up. Therefore, we
believe PTAS can be the first-choice treatment in patients
with CMI, while open revascularization is reserved for
patients in which PTAS fails.
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27:840-4.Submitted Jun 3, 2009; accepted Aug 6, 2009.INVITED COMMENTARYAhmed Abou-Zamzam, Jr., MD, Loma Linda, Calif
Fioole et al report 51 patients treated with percutaneous
angioplasty and stenting (PTAS) for chronic mesenteric ischemia
(CMI), reflecting the authors’ transition towards a PTAS-first
approach to CMI. They report very acceptable primary patency,
secondary patency, and clinical success at 2 years of 60%, 79%, and
56%, respectively. This article is important, because the transition
to endovascular-first treatment for CMI is not limited to this group
but has been observed in many vascular practices. This report
highlights the continued tradeoff of newer, less invasive treat-
ments, and lower morbidity at the expense of durability and higher
reintervention rates compared with open surgery.
A less invasive procedure may tend to overtreat patients with
unclear or minimal symptoms. The current report includes pre-
dominately multivessel disease, but seven patients with single-
vessel disease and “insufficient collaterals” were included. Impor-
tantly, the authors used a multidisciplinary approach to diagnosis,
with the involvement of vascular surgeons, interventional radiolo-
gists, and gastroenterologists. Also, the authors recognize the
emerging role of exercise tonometry. Despite careful consider-
ation, there were two treatment failures due to underlying infec-
tious causes.
In the era of open surgical revascularization, the technical
discussion focused on single vs multiple revascularization and
antegrade vs retrograde bypass. With PTAS, the real discussion
appears to be single-vessel vs multivessel revascularization. Most of
the patients with multivessel disease had single-vessel revascular-
ization, with reliance on visualized collaterals, whereas in only sixrevascularization only. This logic flaw is demonstrated by the open
revascularization procedures necessary in 14% of the patients,
which all involved direct SMA revascularization. The limitation in
crossing chronic occlusions in the visceral vessels needs to be
addressed. This report includes only a single revascularization of a
chronically occluded SMA. Until complete SMA revascularization
is possible, PTAS is not anatomically equivalent to surgical revas-
cularization for CMI.
Surgeons need to carefully view the emerging data on PTAS
for CMI.1-3 The question is whether PTAS is a reasonable first-line
therapy based on the data, or because surgeons now perform
PTAS. From a patient perspective, however, less may be better.
Major morbidity was only 4%. But what is the cost? The authors,
unfortunately, do not provide this information. With a 2-year
primary patency of only 60%, repeat interventions may be the
norm. Within the current health care environment, this is an
excellent opportunity for comparative-effectiveness research.
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